Shopping Cart
- Remove All
- Your shopping cart is currently empty
ASN04885796 (compound IV) is a neuroprotective, specific GPR17 agonist with an EC50=2.27 nM for GPR17-mediated GTPγS binding and can be used to study neurodegenerative diseases such as cerebral ischemia and demyelinating diseases.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $210 | In Stock | |
25 mg | $1,400 | In Stock |
Description | ASN04885796 (compound IV) is a neuroprotective, specific GPR17 agonist with an EC50=2.27 nM for GPR17-mediated GTPγS binding and can be used to study neurodegenerative diseases such as cerebral ischemia and demyelinating diseases. |
Targets&IC50 | GTPγS binding assay:2.27 nM (EC₅₀) |
In vitro | ASN04885796 (compound IV) is a potent GPR17 agonist, exhibiting an EC₅₀ of 2.27 nM in assays measuring GTPγS binding stimulated by GPR17. ASN04885796 possesses neuroprotective effects and serves as a valuable tool for studying neurological disorders[1]. |
Alias | AS-N04885796, ASN 04885796, AS N04885796 |
Molecular Weight | 517.55 |
Formula | C28H28FN5O4 |
Cas No. | 1032892-26-4 |
Smiles | O=C(NCC1OCCC1)C(C2=CC=C(F)C=C2)N(C(=O)CN3N=NC=4C=CC=CC43)C5=CC=C(OC)C=C5 |
Relative Density. | 1.34 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice./Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 80 mg/mL (154.57 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.